This study aimed to evaluate the correlation between in-house and commercial binding-specific IgG antibodies and between in-house and commercial SARS-CoV-2 surrogate virus neutralization tests (sVNT).

SARS-CoV-2 and its variants continue to infect hundreds of thousands every day despite the rollout of effective vaccines. Therefore, it is essential to understand the levels of protection that these ...

A unique and rapid SARS-CoV-2 surrogate virus neutralisation test (sVNT) may be the much needed boost to current COVID-19 investigations to determine infection rate, herd immunity, predicted humoral ...

In a recent study posted to the bioRxiv* pre-print server, researchers in the United States described a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibody ...

A team of international scientists has recently evaluated a surrogate virus neutralization test for severe acute respiratory coronavirus 2 (SARS-CoV-2) and observed that it is highly efficacious for ...

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the broad commercial launch of a SARS ...

Researchers at the Duke-NUS Medical School in Singapore have announced a new blood test for neutralizing antibodies against SARS-CoV2, the virus that causes COVID-19, and have formed public and ...

Evaluation of a 'plaque reduction neutralization test'. Using blood samples from COVID-19 patients, this test detects the antibodies which neutralize the SARS-CoV-2 virus, i.e. stop the virus ...

SARS-CoV-2 vaccine efficacy testing is now facing increasing challenges in the face of an ongoing pandemic with the emergence of new variants and waning vaccine immunity. Evidence supports the ...

On November 26, 2021, the World Health Organization (WHO) named the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first detected in South Africa, as a ...